Actuate Therapeutics (ACTU) Q2 2024 earnings summary

Executive summary

• Focused on developing elraglusib, a GSK-3β inhibitor, for difficult-to-treat cancers, with lead programs in metastatic pancreatic ductal adenocarcinoma and pediatric refractory cancers.

• Completed IPO in August 2024, raising net proceeds of ~$22 million, but cash runway remains insufficient for 12 months of operations.

• No products approved or revenue generated; all resources directed to R&D and clinical development.

Financial highlights

• Net loss for Q2 2024 was $6.6 million, compared to $5.5 million in Q2 2023; six-month net loss was $14.9 million, up from $10.8 million year-over-year.

• Operating expenses for Q2 2024 were $5.4 million, with R&D at $4.4 million and G&A at $1.1 million.

• Cash and cash equivalents as of June 30, 2024 were $0.4 million, excluding IPO proceeds.

• Accumulated deficit reached ~$120 million as of June 30, 2024.

Outlook and guidance

• Current cash, including IPO proceeds, will not fund operations for 12 months; additional capital is required.

• Plans to seek further equity, debt, or partnership funding; failure to secure funds may force reduction or cessation of operations.

• Expects continued operating losses as clinical development progresses.